These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

595 related articles for article (PubMed ID: 22677260)

  • 1. Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).
    Meulenbeld HJ; van Werkhoven ED; Coenen JL; Creemers GJ; Loosveld OJ; de Jong PC; Ten Tije AJ; Fosså SD; Polee M; Gerritsen W; Dalesio O; de Wit R
    Eur J Cancer; 2012 Nov; 48(16):2993-3000. PubMed ID: 22677260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
    de Bono JS; Oudard S; Ozguroglu M; Hansen S; Machiels JP; Kocak I; Gravis G; Bodrogi I; Mackenzie MJ; Shen L; Roessner M; Gupta S; Sartor AO;
    Lancet; 2010 Oct; 376(9747):1147-54. PubMed ID: 20888992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.
    Tannock IF; Fizazi K; Ivanov S; Karlsson CT; Fléchon A; Skoneczna I; Orlandi F; Gravis G; Matveev V; Bavbek S; Gil T; Viana L; Arén O; Karyakin O; Elliott T; Birtle A; Magherini E; Hatteville L; Petrylak D; Tombal B; Rosenthal M;
    Lancet Oncol; 2013 Jul; 14(8):760-8. PubMed ID: 23742877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer.
    Chi KN; Hotte SJ; Yu EY; Tu D; Eigl BJ; Tannock I; Saad F; North S; Powers J; Gleave ME; Eisenhauer EA
    J Clin Oncol; 2010 Sep; 28(27):4247-54. PubMed ID: 20733135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
    Oudard S; Banu E; Beuzeboc P; Voog E; Dourthe LM; Hardy-Bessard AC; Linassier C; Scotté F; Banu A; Coscas Y; Guinet F; Poupon MF; Andrieu JM
    J Clin Oncol; 2005 May; 23(15):3343-51. PubMed ID: 15738542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer.
    Machiels JP; Mazzeo F; Clausse M; Filleul B; Marcelis L; Honhon B; D'Hondt L; Dopchie C; Verschaeve V; Duck L; Verhoeven D; Jousten P; Bonny MA; Moxhon AM; Tombal B; Kerger J
    J Clin Oncol; 2008 Nov; 26(32):5261-8. PubMed ID: 18794543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of docetaxel therapy in elderly (≥70 years) castration resistant prostate cancer patients enrolled in the Netherlands Prostate Study.
    Gerritse FL; Meulenbeld HJ; Roodhart JM; van der Velden AM; Blaisse RJ; Smilde TJ; Erjavec Z; de Wit R; Los M;
    Eur J Cancer; 2013 Oct; 49(15):3176-83. PubMed ID: 23849828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients.
    Buonerba C; Federico P; D'Aniello C; Rescigno P; Cavaliere C; Puglia L; Ferro M; Altieri V; Perdonà S; De Placido S; Di Lorenzo G
    Cancer Chemother Pharmacol; 2011 Jun; 67(6):1455-61. PubMed ID: 21365219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of prognostic factors and efficacy in a phase-II study with docetaxel and estramustine for advanced hormone refractory prostate cancer.
    Nelius T; Reiher F; Lindenmeir T; Klatte T; Rau O; Burandt J; Filleur S; Allhoff EP
    Onkologie; 2005 Nov; 28(11):573-8. PubMed ID: 16249643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
    Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
    Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer.
    Scher HI; Jia X; Chi K; de Wit R; Berry WR; Albers P; Henick B; Waterhouse D; Ruether DJ; Rosen PJ; Meluch AA; Nordquist LT; Venner PM; Heidenreich A; Chu L; Heller G
    J Clin Oncol; 2011 Jun; 29(16):2191-8. PubMed ID: 21483004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer.
    Fizazi K; Higano CS; Nelson JB; Gleave M; Miller K; Morris T; Nathan FE; McIntosh S; Pemberton K; Moul JW
    J Clin Oncol; 2013 May; 31(14):1740-7. PubMed ID: 23569308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
    James ND; Caty A; Borre M; Zonnenberg BA; Beuzeboc P; Morris T; Phung D; Dawson NA
    Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer.
    Fleming MT; Sonpavde G; Kolodziej M; Awasthi S; Hutson TE; Martincic D; Rastogi A; Rousey SR; Weinstein RE; Galsky MD; Berry WR; Wang Y; Boehm KA; Asmar L; Rauch MA; Beer TM
    Clin Genitourin Cancer; 2012 Mar; 10(1):6-14. PubMed ID: 22340631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone.
    Saad F; Ruether D; Ernst S; North S; Cheng T; Perrotte P; Karakiewicz P; Winquist E;
    BJU Int; 2008 Aug; 102(5):551-5. PubMed ID: 18510661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No additional benefit of adding ifosfamide to docetaxel in castration-resistant metastatic prostate cancer.
    Hervonen P; Tulijoki T; Kellokumpu-Lehtinen P
    Anticancer Res; 2012 Aug; 32(8):3305-9. PubMed ID: 22843906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center.
    Zhang HL; Ye DW; Yao XD; Dai B; Zhang SL; Shen YJ; Zhu Y; Zhang W
    Urol Int; 2007; 79(4):307-11. PubMed ID: 18025847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer.
    Heck MM; Thalgott M; Retz M; Wolf P; Maurer T; Nawroth R; Hatzichristodoulou G; Gschwend JE; Kübler H
    BJU Int; 2012 Dec; 110(11 Pt B):E635-40. PubMed ID: 22889368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium.
    Harzstark AL; Rosenberg JE; Weinberg VK; Sharib J; Ryan CJ; Smith DC; Pagliaro LC; Beer TM; Liu G; Small EJ
    Cancer; 2011 Jun; 117(11):2419-25. PubMed ID: 24048789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.